L3. Promoting rehabilitation and recovery management programmes as part of the comprehensive treatment of drug use disorders – sponsored by Chile Chair: Good Afternoon, we are tackling an L3 and L5 for an hour and half. Would like to start on a positive note, I was happy to see a consensus on scheduling in Plenary …
USA
Side event: Global civil society inputs for the 2024 mid-term review and beyond
Organised by the Vienna NGO Committee on Drugs with the support of Australia, Portugal, Slovenia, the United States, the African Union Commission, the European Union, the UNODC Civil Society Unit, the Executive Secretariat of the Inter-American Drug Abuse Control Commission of the Organization of American States, the Africa Civil Society Forum on Drugs, the American …
CND Reconvened 66th Session
Chair: Good Morning. The focus of our discussion pertains to Strategic Management budgetary and administrative motions in the context of our economy. Yesterday, in collaboration with the CCP CJ, we deliberated on the Consolidated budget for the biennium 2024-2025 for the United Nations Office on Drugs and Crime, referencing Containers document 5.2 (2013) and 15/2017, …
2023 CND & CCPCJ Reconvened Session
Secretariat: Distinguished delegates, ladies and gentlemen, As many of you are aware, the term of Her Excellency Ambassador (…), who served as the chair of the CCPCJ 32nd session, concluded at the onset of this conference. On 17 November, the Secretariat received a note from the chair of the African region nominating His Excellency, the Ambassador …
CND Tematic Discussion / Session 12 – Way Forward
Chair: I am grateful for your cooperation earlier this year. We had previously discussed the Resolution, outlining the review process, and collectively decided to convene before he regular committee session. The high-level segment is scheduled for March 14th and 15th, dedicated to assessing the implementation of international drug policy commitments. During this segment, we aim …
CND Thematic Discussion / Session 11 – Low availability of internationally controlled substances for medical & scientific purposes
Chair: Good Morning. Yesterday we had a fruitful discussion on the issues of the consequences and risk associated with non medical use of drugs. Today we will be discussing the low availability of nationally controlled substances for medical and scientific purposes, including for the relief of pain and palliative care. Before we start a discussion, …